The pumps weren’t enough to confer drug resistance on their own, however, and they didn’t guarantee success. For a lucky subset of bacteria that had acquired the genes necessary for tetracycline resistance, however, these pumps chucked out just enough of the antibiotic to give the cell’s protein assembly line a head start.

And once the process got going, it didn’t take much to cross the threshold to tolerance. “In about 100 minutes, [bacteria] can transfer DNA and do all they need to do to acquire resistance,” Lesterlin says. “Then they do as well as cells that started out resistant.”

Because these experiments were conducted in a laboratory and not in a more “natural” system, there’s no guarantee this process is happening during infections, Datta points out. But, she says, given how dense and diverse microbial communities are, and how widespread these efflux pumps are among bacteria, this represents a “very plausible explanation for how bacteria can acquire [many kinds of] antibiotic resistance.”

If that’s the case, efflux pumps could even be aiding and abetting more than conjugation. Bacteria acquire and develop drug tolerance in a variety of ways, sometimes pilfering genes from viruses, slurping up DNA from their surroundings, or simply accruing spontaneous mutations all on their own. These theories haven’t been tested directly, Lesterlin says, but they’re exciting next steps.

Population of drug resistant bacterial cells producing a protein (red) that confers resistance to the antibiotic tetracycline during treatment with tetracycline (green). Image Credit: Courtesy of Christian Lesterlin, University of Lyon

The study’s findings could also prompt renewed interest in designing drugs to inhibit efflux pumps, he says. Though no such treatments are currently available in the clinic, several pump inhibitors are in development for their potential to increase the sensitivity of bacteria to certain antibiotics, which would accumulate more quickly inside of cells in the absence of pumps. In the future, adding a pump blocker to a traditional antibiotic regimen may have the added perk of stymieing the spread of drug resistance, upping the chances of successful treatment.

All this goes to show “just how many weapons bacteria have to facilitate their evolution and adaptation,” Lesterlin says. Despite their petite size, microbes are as flexible and resilient as can be—and that’s not always a bad thing. Bacteria may give us grief, but we also wouldn’t be here without them.

“[These pumps] are important players in bacterial survival and fitness...they offer flexibility and resilience,” Lesterlin says. “That’s most obviously been beneficial for the bacteria, but sometimes that’s good for us as well.”

Receive emails about upcoming NOVA programs and related content, as well as featured reporting about current events through a science lens.

Share this article

National Corporate funding for NOVA is provided by Carlisle Companies. Major funding for NOVA is provided by the NOVA Science Trust, the Corporation for Public Broadcasting, and PBS viewers.